

The Leader in Type 2 Diabetes Reversal

Virta reduces A1c below diabetic threshold while safely eliminating costly medications.

350+ customers trust Virta to deliver:


94% T2D patients reduce or eliminate insulin after 1 year¹

Unmatched Clinical Outcomes 10 peer-reviewed papers

\$503 PPM T2D cost savings over 2 years²

Significant Financial Savings 2:1 ROI in 24 months²

71% retention at year 1³ An Engaging Patient Experience 72 NPS⁴ + patients interact with their health coach nearly every day in the first year⁵



The difference between Diabetes Reversal and Diabetes Management

	Standard Care ¹ One Year Completers	Diabetes Management	Diabetes Reversal ¹ One Year Completers
Alc	♠ 0.2	↓ 0.6 ⁶ One year completers	▶ 1.3
Rx	↑ 7%	▲ 3% ⁷ Increase in medication utilization	₹ 59%
Weight Loss	🖊 0 lbs	1 lbs ⁸ 12 week completers	➡ 31 lbs








Working With





How Virta Works



Working with Virta is Easy

THREE PERFORMANCE GUARANTEES



A1c Target 1.0 R<u>eduction</u>



Weight Target 5% Weight Loss



Diabetes Rx Target 40% Cost Reduction

WHAT YOU DON'T PAY FOR





Engagement



Launch anytime, including off-cycle





No additional implementation work needed



Virta handles all patient marketing and onboarding

- 1. Hallberg SJ et al. Diabetes Theo. 2018; 9(2): 583-612. Outcomes among one year completers. The Virta treatment's reversal target is defined as achieving HbA1c <6.5% without the use of diabetes medications, or only metformin.
- 2. Virta Health, Analysis of Type 2 Diabetes Reversal Cost Savings, Sept 2021 (Virta); Trended 2.5 years using 7.0% for Medical and Rx
- 3. Virta Registry Data, Cumulative 1-year retention rates for all commercial patients, 2021
- 4. Virta Health Registry for Remote Care of Chronic Conditions: 90-day Net Promoter Score among real-world patients for enterprise patients with type 2 diabetes as of 1/6/23. Overall enterprise patient NPS = 71.
- 5. Virta internal data reflecting average number of messages sent between coaches and patients for the 1st year of treatment, as of January 2023.
- 6. Bollyky JB et al. JMIR Diabetes. 2019; 4, e14799 (Outcomes among one year completers (44% retention in Livongo).
- Diabetes-related prescription utilization according to five-client, two-year DiD analysis (slide 34). Livongo presentation at EBPA 2018. https://www.ebpa.org/resources/presentations/2018/Livongo_ EBPA_20SEP2018.pdf
- 8. Bollyky JB et al. J Diabetes Res. 2018; 3961730. (Outcomes at 12 weeks for Livongo + scale group).